June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the ...

MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the ...

(RTTNews) - Ocugen, Inc. (OCGN), Thursday announced the signing of a binding term sheet for licensing OCU400, the company's novel modifier gene therapy for retinitis pigmentosa, to a leading ...

Over the last 7 days, the United States market has dropped 2.6%, yet it has risen by 9.1% over the past year, with earnings forecasted to grow by 14% annually. In such a dynamic environment ...

June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a ...

Sørensen was CEO of Novo Nordisk company from 2000 to 2016. On Stocktwits, retail sentiment around NVO rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message ...

Investing.com -- Shares of Ocugen, Inc. (NASDAQ:OCGN) climbed 11.6% following the announcement of a licensing agreement with a leading Korean pharmaceutical company for the rights to OCU400 ...

Shares of Ocugen Inc. OCGN rallied 2.12% to $0.71 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.41% to 5,916.93 ...